|Nov 16, 2009
|Elite Pharmaceuticals, Inc. To Host Quarterly Conference Call on Wednesday, November 18, 2009
|Northvale, New Jersey, Monday, November 16, 2009: Elite Pharmaceuticals, Inc. (OTC:BB: ELTP) today announced that it has scheduled a conference call for Wednesday, November 18, 2009 at 10:00 AM EST during which management will review quarterly earnings and provide a general corporate update. Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until December 2, 2009 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, improving existing off-patent drug products with and without Elite’s proprietary abuse-resistance technology, and developing generic versions of controlled release drug products with high barriers to entry. Two of Elite’s products, Lodrane 24® and Lodrane 24D®, are marketed by a partner, ECR Pharmaceuticals, a division of HiTech Pharmacal, for treatment of symptoms due to seasonal allergy. Elite’s lead pipeline products are novel sustained release oral formulations of oxycodone for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. ELI-154, a once-daily oxycodone, is now available for commercial licensing. ELI-216, a once-daily abuse resistant oxycodone, is in the final stages of commercial scale-up. Elite, with partners, also has an ANDA filed with the FDA for a generic equivalent of a pain product and has a generic gastrointestinal drug product in clinical development. Several other generic drugs are in formulation development. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. Elite undertakes no obligation to update any forward-looking statements.